세계의 페닐에프린 제제 시장 : 제품 유형별, 투여 경로별, 적응증별, 유통 채널별, 예측(2024-2032년)

Phenylephrine drugs market size is anticipated to register 6.6% CAGR between 2024 and 2032, driven by the increasing prevalence of allergic rhinitis, colds, and sinusitis worldwide. As per World Allergy Organization, allergic rhinitis affects over 400 million individuals, with prevalence rates ranging from 10% to 30% among adults and exceeding 40% among children. As these conditions become more common due to factors, such as urbanization, pollution, and changing climates, the demand for effective decongestants is rising.

Phenylephrine is widely used in over the counter (OTC) medications for its efficacy in relieving nasal and sinus congestion, making it a staple in the pharmaceutical industry. Consumers seeking immediate relief from congestion symptoms also prefer these drugs due to their rapid action and availability without prescription. Pharmaceutical companies are investing in R&D activities to enhance the efficacy, safety, and patient compliance of phenylephrine products. This includes the creation of sustained-release formulations, combination therapies with other active ingredients, and novel delivery systems, such as nasal sprays and inhalers. Regulatory approvals and endorsements by health authorities are ensuring that phenylephrine remains a trusted and widely used drug, further stimulating the market growth.

The industry is classified into product type, route of administration, indication, distribution channel, and region.

Based on product type, the phenylephrine drugs market value from the syrup segment is slated to witness substantial CAGR during 2024-2032. The growth is favored by the widespread acceptance and preference among both consumers and healthcare providers for treating congestion, particularly in pediatric and geriatric populations. Syrups offer a palatable and easy-to-administer alternative to tablets and capsules, making them ideal for children and elderly patients who may have difficulty swallowing pills. The liquid form also allows precise dosing, which is crucial for safe and effective treatment in sensitive groups.

In terms of indication, the phenylephrine drugs industry from the allergic reaction segment is predicted to record decent growth rate through 2032. This is influenced by the rising prevalence of allergies and related symptoms, such as nasal congestion and sinus pressure. As more individuals experience seasonal allergies, allergic rhinitis, and other allergic conditions, there is an increasing demand for reliable decongestants to provide quick relief. The accessibility and effectiveness also makes phenylephrine-based products popular for managing allergy symptoms, driving segment growth.

Asia Pacific phenylephrine drugs industry is poised to depict notable CAGR over the forecast period. This is attributed to the increasing urbanization and associated pollution levels, which contribute to higher incidences of respiratory and allergic conditions. The robust growth of the pharmaceutical industry in countries, such as China, India, and Japan are facilitating the widespread availability and production of phenylephrine drugs. Government initiatives to improve healthcare infrastructure and the rising trend of self-medication will further bolster the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of respiratory diseases
    • 3.2.1.2 Advancement in drug delivery system
    • 3.2.1.3 Increase in shift towards non-sedating decongestants
    • 3.2.1.4 Growing healthcare expenditure
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited efficacy compared to pseudoephedrine
    • 3.2.2.2 Easy availability of alternative drugs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Tablets
• 5.3 Syrups
• 5.4 Eye drops
• 5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral
• 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Cold
• 7.3 Nasal decongestion
• 7.4 Allergic reaction
• 7.5 Eye disease
• 7.6 Other indications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Drug stores & retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Novartis AG
• 10.2 Perrigo Company PLC
• 10.3 Johnson & Johnson Consumer Inc. (Kenvue Inc.)
• 10.4 Proctor & Gamble Co.
• 10.5 Pfizer, Inc.
• 10.6 Foundation Consumer Brands LLC
• 10.7 Mylan N.V.
• 10.8 Torrent Pharmaceuticals, Inc.
• 10.9 GlaxoSmithKline PLC
• 10.10 Bayer AG